By Louis Garguilo, Chief Editor, Outsourced Pharma
A history of bio-pharma outsourcing is writ large upon the chronicles of Cobra Biologics.
It is the story of three European manufacturing facilities—a former AstraZeneca plant; one built by a Swedish pharmacy in the early sixties; and a biotech’s IC-funded dream—converging over decades and serving as a barometer of industry trends. The story touches topics of past and present, including the:
- vicissitudes of big pharma
- emergence of biotechs and biologics
- cycles of venture capital and economies
- growing centricity of outsourcing service providers
We start with the AstraZeneca facility, in Södertälje, Sweden, 30 kilometers southwest of Stockholm, birthplace of Astra AB. “It was and is today a modern, well equipped facility with two cGMP suites fantastically laid out, and scientists with vast experience producing mammalian and microbial products,” says Peter Coleman, CEO of Cobra Biologics, our bellwether CDMO.